Medincell Kötelezettségek 2024

Mit csinál Medincell?

Medincell SA is a leading biotechnology company based in Montpellier, France, specializing in the development and manufacturing of innovative drugs based on its proprietary Intellisome® technology platform. The company was founded in 1999 by Dr. Christophe Douat and has since built an impressive portfolio of products and services. Medincell's business model is based on the development and manufacturing of extended-release drugs through the integration of drugs into the Intellisome® technology platform. This is a novel concept based on the use of polymers that are capable of controlling and slowing down the release of drugs. This allows medications to be administered in a specific dosage and duration, providing greater effectiveness and tolerability for the patient. Medincell has several business areas, including the development of drugs for the treatment of central nervous system (CNS) disorders, including schizophrenia, depression, and chronic pain. The company is also working on the development of drugs for the treatment of infectious diseases and cancer, as well as the development of new technologies for drug manufacturing. Medincell's products include a range of drugs, including Long-Acting Risperidone (a depot preparation for the treatment of schizophrenia), Long-Acting Cabergoline (for the treatment of Parkinson's), and Long-Acting Naltrexone (for the treatment of alcohol and drug addiction). The company also has partnerships with other pharmaceutical companies such as Pierre Fabre, Sanofi, Janssen, and Pfizer for the development of products based on its Intellisome® technology platform. Another important area of Medincell is its service for drug development based on the Intellisome® technology platform. The company offers customers comprehensive support in the development, manufacturing, and approval of extended-release drugs. Customers can choose from a wide range of services, ranging from the identification of active ingredients to the implementation of clinical trials. Overall, Medincell has achieved impressive success in the launch of its products and services based on the Intellisome® technology platform. The company has won several awards for its innovative products and services in the pharmaceutical industry, including the Innovation Award from the European Society of Clinical Microbiology and Infectious Diseases in 2018 and the Excellence in Specialty Pharmaceuticals Award from BioPharm America in 2019. In summary, Medincell SA is a leading company in the biotechnology industry specializing in the development and manufacturing of extended-release drugs based on its Intellisome® technology platform. With an impressive range of products and services and partnerships with several renowned pharmaceutical companies, the company has a promising future as a key player in the pharmaceutical industry. Medincell ist eines der beliebtesten Unternehmen auf Eulerpool.com.